Results from Kaplan–Meier plotter, a website based on Gene Expression Omnibus (GEO) and TCGA datasets [44, 45], indicated that Prame overexpression was associated with worse overall survival (OS) [P = 5e − 5; HR = 1.58 95% confidence interval (CI), 1.27–1.98] in breast cancer and worse OS (P = 4.8e − 10; HR = 1.49; 95% CI, 1.32 − 1.7) in lung cancer (Fig. 5G) [44, 45]. Here, PRAME is linked to lung carcinoma.